Skip to search formSkip to main contentSkip to account menu

TAK 385

Known as: GnRH Antagonist TAK-385, TAK-385, TAK385 
An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Relugolix

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer
This open‐label, phase I dose‐finding study evaluated the gonadotropin‐releasing hormone antagonist, TAK‐385, in Japanese… 
Review
2017
Review
2017
A peek into the drug development scenario of endometriosis - A systematic review.
Review
2017
Review
2017
TO “ QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS : A SYSTEMATIC REVIEW AND META-ANALYSIS ” MORE ATTENTION TO SUBTLE SYMPTOMS , ENVIRONMENTAL CAUSES PREVENTION AND BETTER INFERTILITY TREATMENT CAN…
In their systematic review and meta-analysis articles, Chaman-ara at al (1) confirm that endometriosis negatively affects all… 
2016
2016
Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).
200 Background: Gonadotropin-releasing hormone (GnRH) antagonists achieve rapid decrease in testosterone (T) without transient T… 
2016
2016
Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)
2016
2016
PD28-01 TESTOSTERONE LOWERING, PSA RESPONSE AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED HORMONE SENSITIVE PROSTATE CANCER RECEIVING TAK-385, AN ORAL GNRH ANTAGONIST: PHASE 2 INTERIM ANALYSIS
2015
2015
Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
CONTEXT TAK-385 is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer… 
2015
2015
2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)
2014
2014
Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in…
Highly Cited
2011
Highly Cited
2011
Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent…
We previously discovered an orally active human gonadotropin-releasing hormone (GnRH) receptor antagonist, thieno[2,3-d… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)